Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 04:01 am
Share
Amicogen, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 1,568.91 million compared to KRW 942.21 million a year ago. Net loss was KRW 3,125.2 million compared to KRW 11,114.87 million a year ago. Basic loss per share from continuing operations was KRW 79 compared to KRW 281.5 a year ago. Diluted loss per share from continuing operations was KRW 79 compared to KRW 281.5 a year ago. Basic loss per share was KRW 79 compared to KRW 281.5 a year ago.
For the six months, sales was KRW 3,030.47 million compared to KRW 1,753.77 million a year ago. Net loss was KRW 1,251.23 million compared to KRW 19,824.92 million a year ago. Basic loss per share from continuing operations was KRW 31.5 compared to KRW 502 a year ago. Diluted loss per share from continuing operations was KRW 31.5 compared to KRW 502 a year ago. Basic loss per share was KRW 31.5 compared to KRW 502 a year ago.
Amicogen, Inc. is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâs products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.